April 2014
Volume 55, Issue 13
Free
ARVO Annual Meeting Abstract  |   April 2014
Chitosan Coated Nanostructured Lipid Carriers Containing Dexamethasone Acetate
Author Affiliations & Notes
  • Edson Santos-Neto
    Oftalmologia, Medicina USP, São Paulo, Brazil
  • Márcia Spuri-Ferreira
    Farmacologia, Farmácia USP, São Paulo, Brazil
  • Milton Ruiz-Alves
    Oftalmologia, Medicina USP, São Paulo, Brazil
  • Nádia Bou-Chacra
    Farmacologia, Farmácia USP, São Paulo, Brazil
Investigative Ophthalmology & Visual Science April 2014, Vol.55, 1445. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Edson Santos-Neto, Márcia Spuri-Ferreira, Milton Ruiz-Alves, Nádia Bou-Chacra; Chitosan Coated Nanostructured Lipid Carriers Containing Dexamethasone Acetate. Invest. Ophthalmol. Vis. Sci. 2014;55(13):1445.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: The Chitosan, a polycationic biopolymer with mucoadhesive properties, presents a promising future in the prolonged ocular delivery of drugs. It also presents biodegradability, biocompatibility, nontoxicity and ability to increase paracellular transport of drugs. These properties allow their use as vehicles for ophthalmic formulations.The aim of this study was to develop and characterize NLC coated with chitosan (NLC-C) containing dexamethasone acetate.

Methods: The NLC was formulated using 6.0% (w/w) cetyl palmitate (CP), 4.0% (w/w) capric/caprylic triglycerides (CCP),1.5% (w/w) tween® 80, 2.5% (w/w) lutrol®, 0.25% (w/w) soy lecithin (SL), 0.5% (w/w) sodium dodecyl sulphate (SDS) and 0.05% (w/w) dexamethasone acetate and obtained by high pressure homogenization (HPH). The dexamethasone acetate was incorporated in the lipid phase.CS- NLC was obtained by dissolving 5.0 mL of chitosan dispersion (CS) 0.75% w/v, in 5.0 mL of the nanoparticle suspension under magnetic stirring of 200 rpm for two hours. Measures of mean diameter, polydispersity index (PI) and zeta potential (ZP) were performed on Zetasizer Nano ZS90®. The NLC and CS-NLC were maintained at temperature of 6oC ± 2,0 and were performed in order to evaluate their stability.

Results: The nanoparticles presented mean diameter of 170.5 ± 2.19 nm, PI equal to 0.141 ± 0.01 and ZP of -40.9 ± 0.42 mV. After the coating procedure, the mean diameter, the PI and the ZP were changed to respectively 642.7± 6.08 nm, 0.269 ± 0.02 and +50.4 ± 0.63mV. As expected, the NLC-C presented larger mean diameter and an inversion of the surface charge, which indicated the coating efficiency. The CS- NLC did not show any increase during a 30-day period. It seems that the coating was important to CS-NLC stability.

Conclusions: The values obtained for zeta potential after the coating procedure supports the conclusion that chitosan was adsorbed on the nanoparticle surface. The coating also contributed to the maintenance of CS-NLC stability. The developed system in this study showed interesting properties and therefore it can be proposed as promising drug delivery system to improve the therapeutic efficacy of ophthalmic preparations containing dexamethasone acetate.

Keywords: 607 nanotechnology • 467 clinical laboratory testing • 541 glycoconjugates/glycoproteins  
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×